DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for the management of diabetes and metabolic health in the United States and internationally. The company offers Dexcom G7 and G7 15 Day, an integrated continuous glucose monitoring system; Dexcom G6, a CGM system; Dexcom ONE+ to replace fingerstick blood glucose testing for diabetes treatment decisions; Stelo, a biosensor designed for adults with prediabetes and Type 2 diabetes who do not use insulin; Dexcom Share, a remote monitoring system; and Dexcom Follow application. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.
DexCom, Inc. (DXCM) reported trailing twelve months (TTM) revenue of $4.66B as of December 2025, which represents a 15.6% increase year-over-year. The company's operating margin has expanded to 25.6% from 17.0% a year ago. In terms of profitability, DXCM generated $836.30M in net income. Valuation-wise, the stock trades at a P/E ratio of 31.0x and a Price-to-Sales (P/S) ratio of 5.6x. The company generated $208.70M in free cash flow over the last twelve months, indicating its ability to reinvest in growth or return capital to shareholders. Data based on the most recent quarterly reports.
Quarterly standardized metrics.
Stock price and market valuation
Top-line sales performance
EBITDA and Net Income trends
Price-to-earnings and price-to-sales ratios
Free cash flow generation
Operating and net margin percentages
